Biofabri appoints Rolando Pajón to strengthen the late-stage development of its Tuberculosis Vaccine Candidate

• The appointment comes at a key stage of the project, as MTBVAC advances toward the final phases of clinical development.
• The move is part of Biofabri’s strategy to strengthen its pipeline of innovative medicines aimed at addressing major global health challenges.
• Tuberculosis remains one of the world’s leading infectious diseases, underscoring the urgent need for more effective and accessible vaccines.

O Porriño, Spain, 17 February 2026 – Biofabri, the human vaccines subsidiary of the biopharmaceutical group Zendal, has appointed Rolando Pajón Feyt to its executive team in order to reinforce the final stage of clinical development of its tuberculosis vaccine candidate, MTBVAC.

The appointment comes at a decisive moment for the program, marked by progress toward the final phases of clinical evaluation and by the need to integrate scientific excellence, clinical development, regulatory strategy and market access planning. Pajón Feyt will serve as Chief Medical and Scientific Officer (CMSO) of Biofabri.

With more than 30 years of experience in vaccines and immunotherapies, Pajón’s career spans the full lifecycle of innovative medicines, from basic and translational research to regulatory approval and commercial launch. Throughout his professional trajectory, he led international teams responsible for generating and analyzing key data for regulatory submissions, as well as presenting findings to health authorities, scientific communities and investors.

An expert in mRNA vaccines, infectious diseases and immuno-oncology, he played a significant role in the development of some of the first vaccines based on this technology and contributed to expanding access to COVID-19 vaccines in Latin America. He began his professional career in Cuba and later worked for more than 18 years in the United States, maintaining collaborations with international organizations such as the World Health Organization (WHO) and the Pan American Health Organization (PAHO), as well as with European and American scientific networks.

Esteban Rodríguez, Chief Executive Officer (CEO) of Biofabri, stated: “Rolando Pajón’s appointment reinforces our commitment to international talent and provides strategic momentum as we enter the final stage of MTBVAC’s development. Tuberculosis continues to represent a major global health challenge, and our commitment is to contribute innovative and accessible solutions.”

Rolando Pajón is the author or co-author of more than 80 scientific publications in high-impact journals, holds over 14 patents, and has contributed to the development of specialized educational materials in vaccinology.